Clinical trials: Platelet Inhibition
Esophageal Cancer, Intensity-modulated Radiation Therapy
The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients
The goal of this interventional study is to explore the protective effect of prophylactic TPO combined with bone marrow sparing (BMS)-IMRT in patients with esophageal cancer undergoing concurrent chemoradiotherapy.
- Conditions
- Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy, Thrombocytopenia
- Trial name
- NCT05944809
- Testing
- rhTPO
- Where
- China
- Volunteers
- 32 people
- Sponsor
- JIANYANG WANG
Coronary Artery Disease
Cross-over Study of Coronary Risk Factors With a Polypill
Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary…
- Trial name
- POLICROSS (NCT05030818)
- Testing
- Polypill of acetylsalicylic acid, ramipril and atorvastatin, Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin
- Where
- Spain
- Volunteers
- 88 people
- Sponsor
- Fundación EPIC
Acute Coronary Syndrome
Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time
In full responders to clopidogrel scheduled to undergo PCI for NSTEACS, the use of abciximab bolus only plus 600 mg clopidogrel loading dose will result in a non-inferior inhibition of platelet aggregation after 4 hours as…
- Trial name
- FABOLUS (NCT00929279)
- Testing
- bolus+infusion, abciximab bolus only regimen
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Università degli Studi di Ferrara
Acquired Platelet Disorder
Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel
The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.
- Trial name
- NCT01839968
- Testing
- Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- University Hospital, Geneva
Surgery
Association Between Perioperative Platelet Function and Major Adverse Perioperative Events
This study will examine the degree of blood thinning (platelet function) in patients coming for non-cardiac surgery on antiplatelet agents using platelet function tests called thromboelastography (TEG) and platelet mapping assay…
- Trial name
- NCT00901030
- Testing
- Blood drawn
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- McMaster University
Arterial Occlusive Diseases, Coronary Artery Disease
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis
- Trial name
- TRIP-PCI (NCT02561000)
- Testing
- PZ-128
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Healthy
The Impact of Grapefruit Juice on the Response to Clopidogrel
This study will measure the percentage of platelet aggregation inhibition with a loading dose of clopidogrel (300 mg) using the VerifyNow Assay System in healthy volunteers who have drank 11 oz of grapefruit juice.
- Trial name
- NCT00817999
- Testing
- Grapefruit juice, Clopidogrel 75 mg/day, Clopidogrel 300 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Creighton University
Postoperative Thromboembolism
Effect of Tumescent Lidocaine on Platelet Function
The purpose of this study is to evaluate the effect of lidocaine, delivered into subcutaneous tissue for tumescent local anesthesia, on platelet activation following the tumescent liposuction.
- Trial name
- NCT01463280
- Testing
- tumescent lidocaine infiltration
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Klein, Jeffrey A., M.D.
Cardiovascular Diseases
Effect of Ingesting a Tomato Pomace Extract on Platelet Aggregation
This study evaluates the acute and longer term effects of a tomato pomace extract on platelet aggregation in health subjects.
- Trial name
- Tomasa (NCT02986165)
- Testing
- Low dose pomace extract, High dose pomace extract
- Where
- Chile
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Centro de Estudios en Alimentos Procesados
Atherosclerosis, Acute Coronary Syndrome (ACS)
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a…
- Trial name
- Platform (NCT00385138)
- Testing
- Cangrelor, clopidogrel
- Where
- United States
- Volunteers
- 5,364 people
- Sponsor
- The Medicines Company
Diabetes Mellitus, Type 2, Coronary Artery Disease
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patients with DM who are known to have…
- Trial name
- OPTIMUS-6 (NCT03437044)
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Coronary Artery Disease, Myocardial Infarction
Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis
The primary objective of this study is to establish a cut off level of platelet inhibition that separates patients with or without previous stent occlusion with acute clinical onset while on aspirin and clopidogrel treatment…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Stent Thrombosis, Heart Diseases
- Trial name
- TOPAS-1 (NCT00914368)
- Testing
- Clopidogrel
- Where
- Sweden
- Volunteers
- 450 people
- Sponsor
- Uppsala University
Platelet Dysfunction Due to Drugs
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.
Hypothesis: Trimetazidine improves Clopidogrel response in patients. The investigators postulate that the inhibition of platelet aggregation in response to Clopidogrel may be accentuated by Trimetazidine, i.e.
- Trial name
- TRACER (NCT03603249)
- Testing
- Trimetazidine
- Where
- Trinidad and Tobago
- Volunteers
- 24 people
- Sponsor
- The University of The West Indies
Acute Coronary Syndrome (ACS)
Maintenance of Platelet Inhibition With Cangrelor
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
- Trial name
- Bridge (NCT00767507)
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome, Atrial Fibrillation
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
The selection of the optimal antithrombotic therapy in patients with nonvalvular atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is challenging.
- Trial name
- EPIDAURUS (NCT04981041)
- Testing
- Prasugrel or Ticagrelor, Clopidogrel
- Where
- 37 sites in Austria, Germany
- Volunteers
- 602 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Acute Myocardial Infarction
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug.
- Trial name
- NCT03487445
- Testing
- Selatogrel 8 mg, Selatogrel 16 mg
- Where
- 6 sites in Belgium, Israel and 1 more
- Volunteers
- 48 people
- Sponsor
- Viatris Innovation GmbH
Platelet Inhibition, Coronary Stent Implantation
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode…
- Trial name
- IDEAL-PCI (NCT01515345)
- Testing
- prasugrel or ticagrelor, Clopidogrel
- Where
- Austria
- Volunteers
- 1,008 people
- Sponsor
- Kaiser Franz Josef Hospital
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Chronic Kidney Disease, Stable Angina
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
Impaired renal function is associated with reduced responsiveness to clopidogrel. There are no studies which have shown a means by which to overcome platelet hyporesponsiveness in patients with chronic kidney disease (CKD).
- Trial name
- CKD (NCT01328470)
- Testing
- Clopidogrel, cilostazol
- Where
- South Korea
- Volunteers
- 85 people
- Sponsor
- Kyunghee University Medical Center